FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Setsuko Chambers

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Gene Expression Regulation, Neoplastic

Co-author Network

Publications

TOP 3
Anna C Nelson-Moseke; Denise J Roe; Setsuko K Chambers; Haiyan Cui; Joanne M Jeter; Christina M Laukaitis
An unusual BRCA mutation distribution in a high risk cancer genetics clinic.
Amanda F Baker; David S Alberts; Mary C Clouser; Janice L Cohen; Haiyan Cui; Cynthia Laughren; Denise J Roe; Heather M Wright; Setsuko K Chambers
Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer.
Yiying Wang; Yue Wang; Setsuko K Chambers; Janiel Cragun; Kenneth Hatch; Jie Li; Wenxin Zheng
Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Setsuko Chambers (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Anna C Nelson-Moseke; Denise J Roe; Setsuko K Chambers; Haiyan Cui; Joanne M Jeter; Christina M Laukaitis
An unusual BRCA mutation distribution in a high risk cancer genetics clinic.
Familial cancer 2013;12(1):83-7.
2013: Amanda F Baker; David S Alberts; Mary C Clouser; Janice L Cohen; Haiyan Cui; Cynthia Laughren; Denise J Roe; Heather M Wright; Setsuko K Chambers
Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer.
Investigational new drugs 2013;31(1):160-6.
2013: Yiying Wang; Yue Wang; Setsuko K Chambers; Janiel Cragun; Kenneth Hatch; Jie Li; Wenxin Zheng
Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium.
Journal of hematology & oncology 2013;6():22.
2012: Setsuko K Chambers; Jesse D Martinez
The significance of p53 isoform expression in serous ovarian cancer.
Future oncology (London, England) 2012;8(6):683-6.
2012: Setsuko K Chambers; H-H Sherry Chow; Mary C Clouser; Janice L Cohen; Janiel M Cragun; Haiyan Cui; Kenneth D Hatch; Mike F Janicek; Cynthia Laughren; Heather M Wright; Nisreen Abu Shahin; David S Alberts
Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(9):2668-78.
2012: Beth Y Karlan; Charles A Leath; Raj V Nagarkar; Hoa Nguyen; Amit Oza; Charles H Pippitt; Diane M Provencher; Gary E Richardson; Daniel E Stepan; Yu-Nien Sun; Marjan Tassoudji; John V Brown; Martin Buck; Setsuko K Chambers; Allan Covens; Margaret Davy; Prafull Ghatage; Vincent L Hansen; David M Weinreich; Ignace B Vergote
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(4):362-71.
2011: Jie Li; Shujie Pang; Li Xiang; Nisreen Abushahin; Setsuko K Chambers; Oluwole Fadare; Beihua Kong; Wenxin Zheng
Tubal origin of 'ovarian' low-grade serous carcinoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2011;24(11):1488-99.
2011: Eugene P Toy; Ho-Hyung Woo; Masoud Azodi; Tiffany Lamb; William J Roy; Setsuko K Chambers
Inhibition of the c-fms proto-oncogene autocrine loop and tumor phenotype in glucocorticoid stimulated human breast carcinoma cells.
Breast cancer research and treatment 2011;129(2):411-9.
2011: Rebecca McCaffrey; Mert Bahtiyar; Ernest I Kohorn; Joseph T Chambers; Peter E Schwartz; Setsuko K Chambers
Neoadjuvant and adjuvant chemotherapy of cervical cancer: mature results of the phase 2 PBM-PFU protocol.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011;21(3):535-44.
2011: Sharon X Liang; Micheal Pearl; Shu Liang; Li Xiang; Lin Jia; Binlie Yang; Oluwole Fadare; Peter E Schwartz; Setsuko K Chambers; Beihua Kong; Wenxin Zheng
Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger.
International journal of cancer. Journal international du cancer 2011;128(4):763-70.
2011: Ho-Hyung Woo; Xiaofang Yi; Tiffany Lamb; Ina Menzl; Terri Baker; David J Shapiro; Setsuko K Chambers
Posttranscriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer.
Molecular and cellular biology 2011;31(1):215-25.
2010: Lisa M Hess; Setsuko K Chambers; Kenneth Hatch; Alton Hallum; Mike F Janicek; Joseph Buscema; Matthew Borst; Cynthia Johnson; Lisa Slayton; Yuda Chongpison; David S Alberts
Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer.
The journal of supportive oncology 2010;8(6):252-8.
2010: Setsuko K Chambers; Mary C Clouser; Amanda F Baker; Denise J Roe; Haiyan Cui; Molly Brewer; Kenneth D Hatch; Michael S Gordon; Mike F Janicek; Jeffrey D Isaacs; Alan N Gordon; Raymond B Nagle; Heather M Wright; Janice L Cohen; David S Alberts
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(21):5320-8.
2010: Rebecca L Klein; Amanda R Brown; Christian M Gomez-Castro; Setsuko K Chambers; Janiel M Cragun; Lauren Grasso-Lebeau; Julie Lang
Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature review.
Journal of Cancer 2010;1():27-31.
2009: Setsuko K Chambers
Role of CSF-1 in progression of epithelial ovarian cancer.
Future oncology (London, England) 2009;5(9):1429-40.
2009: Ho-Hyung Woo; Y Zhou; X Yi; Cynthia L David; Wenxin Zheng; Maureen Gilmore-Hebert; Harriet M Kluger; E Cagnur Ulukus; T Baker; J B Stoffer; Setsuko K Chambers
Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer.
Oncogene 2009;28(9):1176-86.
2009: Xiaofang Yi; Yi Zhou; Wenxin Zheng; Setsuko K Chambers
HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer.
The Australian & New Zealand journal of obstetrics & gynaecology 2009;49(1):93-8.
2009: Eugene P Toy; Masoud Azodi; Nancy L Folk; Christina M Zito; Caroline J Zeiss; Setsuko K Chambers
Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor.
Neoplasia (New York, N.Y.) 2009;11(2):136-44.
2009: Mary Clouser; Lisa M Hess; Setsuko K Chambers
Biomarker targets and novel therapeutics.
Cancer treatment and research 2009;149():85-105.
2008: Yi Zhou; Xiaofang Yi; Jha'nae B Stoffer; Nathalie Bonafe; Maureen Gilmore-Hebert; Jessica McAlpine; Setsuko K Chambers
The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is both regulated and controls colony-stimulating factor-1 messenger RNA stability in ovarian cancer.
Molecular cancer research : MCR 2008;6(8):1375-84.
2008: Wenxin Zheng; Setsuko K Chambers
Histopathology of endometrial hyperplasia and endometrial carcinoma. An update by Dr LC Horn et al in Annals of Diagnostic Pathology 2007;11:297-311.
Annals of diagnostic pathology 2008;12(3):231-2; author reply 232-3.
2007: Wenxin Zheng; Sharon X Liang; Xiaofang Yi; E Cagnur Ulukus; John Davis; Setsuko K Chambers
Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2007;26(1):38-52.
2006: Oluwole Fadare; Sharon X Liang; E Cagnur Ulukus; Setsuko K Chambers; Wenxin Zheng
Precursors of endometrial clear cell carcinoma.
The American journal of surgical pathology 2006;30(12):1519-30.
2005: Nathalie Bonafe; Maureen Gilmore-Hebert; Nancy L Folk; Masoud Azodi; Yi Zhou; Setsuko K Chambers
Glyceraldehyde-3-phosphate dehydrogenase binds to the AU-Rich 3' untranslated region of colony-stimulating factor-1 (CSF-1) messenger RNA in human ovarian cancer cells: possible role in CSF-1 posttranscriptional regulation and tumor phenotype.
Cancer research 2005;65(9):3762-71.
2005: Setsuko K Chambers
Systematic lymphadenectomy in advanced epithelial ovarian cancer: two decades of uncertainty resolved.
Journal of the National Cancer Institute 2005;97(8):548-9.
2005: Eugene P Toy; Nathalie Bonafe; Asim Savlu; Caroline J Zeiss; Wenxin Zheng; Maryann B Flick; Setsuko K Chambers
Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis.
Clinical & experimental metastasis 2005;22(1):1-9.
2004: Michael G Kelly; David M O'Malley; Pei Hui; Jessica N McAlpine; J Dziura; Thomas Rutherford; Masoud Azodi; Setsuko K Chambers; Peter E Schwartz
Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
Gynecologic oncology 2004;95(3):469-73.
2004: Michael H Bloch; Wei Chan Hwang; Joachim M Baehring; Setsuko K Chambers
Paraneoplastic limbic encephalitis: ovarian cancer presenting as an amnesic syndrome.
Obstetrics and gynecology 2004;104(5 Pt 2):1174-7.
2004: Sharon X Liang; Setsuko K Chambers; Liang Cheng; Shaopo Zhang; Yi Zhou; Wenxin Zheng
Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features.
International journal of surgical pathology 2004;12(4):319-31.
2004: Wenxin Zheng; Sharon X Liang; Herbert Yu; Thomas Rutherford; Setsuko K Chambers; Peter E Schwartz
Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
International journal of surgical pathology 2004;12(3):207-23.
2004: Setsuko K Chambers; Christina M Ivins; Barry M Kacinski; Richard B Hochberg
An unexpected effect of glucocorticoids on stimulation of c-fms proto-oncogene expression in choriocarcinoma cells that express little glucocorticoid receptor.
American journal of obstetrics and gynecology 2004;190(4):974-85.
2004: Jacob Tangir; Nathalie Bonafe; Maureen Gilmore-Hebert; Octavian Henegariu; Setsuko K Chambers
SGK1, a potential regulator of c-fms related breast cancer aggressiveness.
Clinical & experimental metastasis 2004;21(6):477-83.
2003: Joseph T Chambers; Thomas Rutherford; Peter E Schwartz; Maria Luisa Carcangiu; Setsuko K Chambers; L Baker
A pilot study of topotecan in the treatment of serous carcinoma of the uterus.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(2):216-22.
2003: Omer T Yalcin; Thomas Rutherford; Setsuko K Chambers; Joseph T Chambers; Peter E Schwartz
Vaginal intraepithelial neoplasia: treatment by carbon dioxide laser and risk factors for failure.
European journal of obstetrics, gynecology, and reproductive biology 2003;106(1):64-8.
2002: Bernadette Cracchiolo; Hartmut M Hanauske-Abel; Peter E Schwartz; Joseph T Chambers; Bart Holland; Setsuko K Chambers
Procollagen-derived biomarkers in malignant ascites of ovarian cancer. Independent prognosticators for progression-free interval and survival.
Gynecologic oncology 2002;87(1):24-33.
2001: E P Toy; Joseph T Chambers; Barry M Kacinski; Maryann B Flick; Setsuko K Chambers
The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma.
Gynecologic oncology 2001;80(2):194-200.
2000: Matthew Cooperberg; Setsuko K Chambers; Thomas Rutherford; Harris E Foster
Cystic pelvic pathology presenting as falsely elevated post-void residual urine measured by portable ultrasound bladder scanning: report of 3 cases and review of the literature.
Urology 2000;55(4):590.
1999: Masoud Azodi; Setsuko K Chambers; Thomas Rutherford; Ernest I Kohorn; Peter E Schwartz; Joseph T Chambers
Adenocarcinoma in situ of the cervix: management and outcome.
Gynecologic oncology 1999;73(3):348-53.
1998: Setsuko K Chambers; Christina M Ivins; Maria Luisa Carcangiu
Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.
International journal of cancer. Journal international du cancer 1998;79(5):449-54.
1998: FV Price; Setsuko K Chambers; Maria Luisa Carcangiu; Ernest I Kohorn; Peter E Schwartz; Joseph T Chambers
CA 125 may not reflect disease status in patients with uterine serous carcinoma.
Cancer 1998;82(9):1720-5.
1998: Setsuko K Chambers
The gynecologic oncology model: research.
Surgical oncology clinics of North America 1998;7(2):255-62.
1998: Bruce C Turner; Jonathan Knisely; Barry M Kacinski; Bruce G Haffty; Andrew A Gumbs; Kenneth B Roberts; A H Frank; Richard E Peschel; Thomas Rutherford; B Edraki; Ernest I Kohorn; Setsuko K Chambers; Peter E Schwartz; Lynn D Wilson
Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
International journal of radiation oncology, biology, physics 1998;40(1):77-84.
1997: Setsuko K Chambers; Christina M Ivins; Maria Luisa Carcangiu
Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor related to the actions of CSF-1.
International journal of cancer. Journal international du cancer 1997;74(6):571-5.
1997: Setsuko K Chambers; Barry M Kacinski; Christina M Ivins; Maria Luisa Carcangiu
Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(6):999-1007.
1997: Setsuko K Chambers; Joseph T Chambers; C A Davis; Ernest I Kohorn; Peter E Schwartz; M I Lorber; Robert E Handschumacher; Giuseppe Pizzorno
Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1945-52.
1996: E Resnik; Setsuko K Chambers; Maria Luisa Carcangiu; Ernest I Kohorn; Peter E Schwartz; I T Chambers
Malignant uterine smooth muscle tumors: role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy.
Journal of surgical oncology 1996;63(3):145-7.
1996: Setsuko K Chambers; C A Davis; Joseph T Chambers; Peter E Schwartz; M I Lorber; R E Hschumacher
Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1699-704.
1996: Setsuko K Chambers; C A Davis; Peter E Schwartz; Ernest I Kohorn; Joseph T Chambers
Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1693-7.
1996: I Cass; E Resnik; Joseph T Chambers; Setsuko K Chambers; Maria Luisa Carcangiu; Ernest I Kohorn; Peter E Schwartz
Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa.
Gynecologic oncology 1996;61(3):309-14.
1996: TG Zreik; Joseph T Chambers; Setsuko K Chambers
Parametrial involvement, regardless of nodal status: a poor prognostic factor for cervical cancer.
Obstetrics and gynecology 1996;87(5 Pt 1):741-6.
1996: D A Fishman; K B Roberts; Joseph T Chambers; Ernest I Kohorn; Peter E Schwartz; Setsuko K Chambers
Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium.
Gynecologic oncology 1996;61(2):189-96.
1996: Joseph T Chambers; Setsuko K Chambers; Ernest I Kohorn; Maria Luisa Carcangiu; Peter E Schwartz
Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide.
Gynecologic oncology 1996;60(3):438-42.
1995: Setsuko K Chambers; R E Gertz; Christina M Ivins; Barry M Kacinski
The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Cancer 1995;75(7):1627-33.
1995: Setsuko K Chambers; Y Wang; R E Gertz; Barry M Kacinski
Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.
Cancer research 1995;55(7):1578-85.
1995: E Resnik; Setsuko K Chambers; Maria Luisa Carcangiu; Ernest I Kohorn; Peter E Schwartz; Joseph T Chambers
A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed müllerian tumors (MMT) of the uterus.
Gynecologic oncology 1995;56(3):370-5.
1995: D A Fishman; Setsuko K Chambers; Peter E Schwartz; Ernest I Kohorn; Joseph T Chambers
Extramammary Paget's disease of the vulva.
Gynecologic oncology 1995;56(2):266-70.
1995: Leslie Scoutt; Shirley M McCarthy; Stuart D Flynn; Robert C Lange; F Long; Robert C Smith; Setsuko K Chambers; Ernest I Kohorn; P Schwartz; Joseph T Chambers
Clinical stage I endometrial carcinoma: pitfalls in preoperative assessment with MR imaging. Work in progress.
Radiology 1995;194(2):567-72.
1994: Setsuko K Chambers; Barry M Kacinski
Messenger RNA decay of macrophage colony-stimulating factor in human ovarian carcinomas in vitro.
Journal of the Society for Gynecologic Investigation 1994;1(4):310-6.
1994: Setsuko K Chambers; Y Wang; M Gilmore-Hebert; Barry M Kacinski
Post-transcriptional regulation of c-fms proto-oncogene expression by dexamethasone and of CSF-1 in human breast carcinomas in vitro.
Steroids 1994;59(9):514-22.
1994: Setsuko K Chambers; L Lamb; Ernest I Kohorn; Peter E Schwartz; Joseph T Chambers
Chemotherapy of recurrent/advanced cervical cancer: results of the Yale University PBM-PFU protocol.
Gynecologic oncology 1994;53(2):161-9.
1993: FV Price; Setsuko K Chambers; Maria Luisa Carcangiu; Ernest I Kohorn; Peter E Schwartz; Joseph T Chambers
Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC).
Gynecologic oncology 1993;51(3):383-9.
1993: Setsuko K Chambers; M Gilmore-Hebert; Y Wang; Sofya Rodov; Edward J Benz; Barry M Kacinski
Posttranscriptional regulation of colony-stimulating factor-1 (CSF-1) and CSF-1 receptor gene expression during inhibition of phorbol-ester-induced monocytic differentiation by dexamethasone and cyclosporin A: potential involvement of a destabilizing protein.
Experimental hematology 1993;21(10):1328-34.
1993: TL Yang-Feng; H Han; K C Chen; S B Li; Elizabeth B Claus; Maria Luisa Carcangiu; Setsuko K Chambers; J T Chambers; Peter E Schwartz
Allelic loss in ovarian cancer.
International journal of cancer. Journal international du cancer 1993;54(4):546-51.
1993: FV Price; Setsuko K Chambers; Joseph T Chambers; Maria Luisa Carcangiu; Peter E Schwartz; Ernest I Kohorn; E Richard Stanley; Barry M Kacinski
Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival.
American journal of obstetrics and gynecology 1993;168(2):520-7.
1992: A R Mayer; Setsuko K Chambers; E Graves; C Holm; P C Tseng; B E Nelson; Peter E Schwartz
Ovarian cancer staging: does it require a gynecologic oncologist?
Gynecologic oncology 1992;47(2):223-7.
1992: Setsuko K Chambers; M Gilmore-Hebert; Barry M Kacinski; Edward J Benz
Changes in Na,K-ATPase gene expression during granulocytic differentiation of HL60 cells.
Blood 1992;80(6):1559-64.
1992: P E Schwartz; Setsuko K Chambers; Joseph T Chambers; E Kohorn; S McIntosh
Ovarian germ cell malignancies: the Yale University experience.
Gynecologic oncology 1992;45(1):26-31.
1992: Barry M Kacinski; A G Mayer; Bonnie L King; Darryl L Carter; Setsuko K Chambers
NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms.
Gynecologic oncology 1992;44(3):245-53.
1991: A H Frank; P C Tseng; Bruce G Haffty; D P Papadopoulos; Barry M Kacinski; S W Dowling; Maria Luisa Carcangiu; Ernest I Kohorn; Joseph T Chambers; Setsuko K Chambers
Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma.
Cancer 1991;68(7):1516-9.
1991: Barry M Kacinski; Setsuko K Chambers
Molecular biology of ovarian cancer.
Current opinion in oncology 1991;3(5):889-900.
1991: Setsuko K Chambers; Joseph T Chambers; R Kier; Richard E Peschel
Sequelae of lateral ovarian transposition in irradiated cervical cancer patients.
International journal of radiation oncology, biology, physics 1991;20(6):1305-8.
1991: Barry M Kacinski; K A Scata; Darryl L Carter; L D Yee; Eva Sapi; Bonnie L King; Setsuko K Chambers; M A Jones; M H Pirro; E Richard Stanley
FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro.
Oncogene 1991;6(6):941-52.
1990: Setsuko K Chambers; Joseph T Chambers; C Holm; Richard E Peschel; Peter E Schwartz
Sequelae of lateral ovarian transposition in unirradiated cervical cancer patients.
Gynecologic oncology 1990;39(2):155-9.
1990: Barry M Kacinski; Setsuko K Chambers; E Richard Stanley; Darryl L Carter; P Tseng; K A Scata; D H Chang; M H Pirro; J T Nguyen; A Ariza
The cytokine CSF-1 (M-CSF) expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients.
International journal of radiation oncology, biology, physics 1990;19(3):619-26.
1990: Barry M Kacinski; Darryl L Carter; K Mittal; L D Yee; K A Scata; L Donofrio; Setsuko K Chambers; K I Wang; T Yang-Feng; L R Rohrschneider
Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1.
The American journal of pathology 1990;137(1):135-47.
1990: Joseph T Chambers; Setsuko K Chambers; I M Voynick; Peter E Schwartz
Neoadjuvant chemotherapy in stage X ovarian carcinoma.
Gynecologic oncology 1990;37(3):327-31.
1990: Joseph T Chambers; Setsuko K Chambers; Peter E Schwartz
Correlation between measured creatinine clearance and calculated creatinine clearance in ovarian cancer patients.
Gynecologic oncology 1990;36(1):66-8.
1989: Setsuko K Chambers; R L Chopyk; Joseph T Chambers; Peter E Schwartz; T P Duffy
Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer.
Cancer 1989;64(12):2459-61.
1989: Setsuko K Chambers; W N Hait; Barry M Kacinski; S R Keyes; Robert E Handschumacher
Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues.
Cancer research 1989;49(22):6275-9.
1989: R Kier; Setsuko K Chambers
Surgical transposition of the ovaries: imaging findings in 14 patients.
AJR. American journal of roentgenology 1989;153(5):1003-6.
1989: Barry M Kacinski; E Richard Stanley; Darryl L Carter; Joseph T Chambers; Setsuko K Chambers; Ernest I Kohorn; Peter E Schwartz
Circulating levels of CSF-1 (M-CSF) a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms.
International journal of radiation oncology, biology, physics 1989;17(1):159-64.
1989: Barry M Kacinski; Darryl L Carter; Ernest I Kohorn; K Mittal; R S Bloodgood; J Donahue; C A Kramer; D Fischer; R Edwards; Setsuko K Chambers
Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors.
The Yale journal of biology and medicine 1989;62(4):379-92.
1989: Peter E Schwartz; Joseph T Chambers; Ernest I Kohorn; Setsuko K Chambers; H Weitzman; I M Voynick; N MacLusky; Frederick Naftolin
Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial.
Cancer 1989;63(6):1074-8.
1989: C Kramer; Richard E Peschel; N Goldberg; Ernest I Kohorn; Joseph T Chambers; Setsuko K Chambers; Peter E Schwartz
Radiation treatment of FIGO stage IVA carcinoma of the cervix.
Gynecologic oncology 1989;32(3):323-6.
1989: Peter E Schwartz; Setsuko K Chambers; Joseph T Chambers; K Tilton; R Foemmel
CA 125 in peritoneal washings and fluid: correlation with plasma CA 125 and peritoneal cytology.
Obstetrics and gynecology 1989;73(3 Pt 1):339-42.
1989: Setsuko K Chambers; Stuart D Flynn; S A Del Prete; Joseph T Chambers; Peter E Schwartz
Bleomycin, vincristine, mitomycin C, and cis-platinum in gynecologic squamous cell carcinomas: a high incidence of pulmonary toxicity.
Gynecologic oncology 1989;32(3):303-9.
1988: Setsuko K Chambers; Joseph T Chambers; E I Kohorn; R Lawrence; Peter E Schwartz
Evaluation of the role of second-look surgery in ovarian cancer.
Obstetrics and gynecology 1988;72(3 Pt 1):404-8.
1988: Laurence A Cole; Y X Wang; M Elliott; M Latif; Joseph T Chambers; Setsuko K Chambers; Peter E Schwartz
Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
Cancer research 1988;48(5):1356-60.
1987: Peter E Schwartz; Setsuko K Chambers; Joseph T Chambers; J Gutmann; N Katopodis; R Foemmel
Circulating tumor markers in the monitoring of gynecologic malignancies.
Cancer 1987;60(3):353-61.
1987: Setsuko K Chambers; D S Kapp; R E Peschel; R Lawrence; M Merino; E I Kohorn; P E Schwartz
Prognostic factors and sites of failure in FIGO Stage I, Grade 3 endometrial carcinoma.
Gynecologic oncology 1987;27(2):180-8.